ArticleJournal of nanobiotechnology2025
3D dynamic magnetic microfluidic chip for efficient plasma extracellular vesicle enrichment and machine learning-based multiparametric diagnosis of hepatocellular carcinoma.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Extracellular vesicle biomarkers: current status and future perspectives as novel tools in liquid biopsy.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide, with early diagnosis critical for improving outcomes. Current diagnostic tools, including serum biomarkers and imaging techniques, exhibit limited sensitivity and specificity. Although extracellular vesicles (EVs) have emerged as a promising source of cancer biomarkers, their clinical utility is hampered by inefficient enrichment technologies.To overcome this limitation, a microfluidic platform was developed to enable rapid and efficient EV capture.
resultsThe 3D DynaMag-EV capture chip was developed, integrating active and passive micromixing strategies for efficient capture of plasma-derived EVs. This platform employs tentacle-like magnetic particles conjugated with aptamers as the capture matrix, in combination with a 3D porous chip structure and an alternating, non-uniform magnetic field, thereby significantly enhancing EVs-capture substrate interactions and effectively addressing the limitations in collision efficiency and mass transfer. The 3D DynaMag-EV capture chip enabled rapid EV enrichment within 20 minutes, achieving high capture efficiency and purity.Transcriptome analysis of plasma EVs enriched by the developed chip identified two HCC-specific long non-coding RNAs (KCNQ1-AS1 and LINC01785) in HCC, liver cirrhosis or hepatitis patients, and healthy controls. A diagnostic model based on these two markers (EVlncRNA score) demonstrated robust performance, achieving an area under the curve (AUC) exceeding 0.80 in all cohorts and surpassing alpha-fetoprotein (AFP). Considering the accessibility of routine clinical laboratory indicators, a multiparametric diagnostic model was further developed by integrating the EVlncRNA score with conventional clinical variables (patient age, AFP , gamma-glutamyl transferase, and albumin levels) using machine learning, which enhanced the diagnostic accuracy (AUC>0.90).
conclusionThis study developed an integrated microfluidic platform for rapid EV isolation and established an EVlncRNA Score model, enabling highly efficient early HCC detection, even in AFP-negative cases. A multiparametric diagnostic model further improved accuracy, offering a promising tool for clinical HCC screening. This strategy presents a robust, non-invasive liquid biopsy strategy with significant potential for early HCC detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.